Spontaneous MxA mRNA level predicts relapses in patients with recently diagnosed MS

Neurology

Volumn 75, Issue 14, 2010, Pages 1228-1233

  Van Der Voort, L F ^a   Vennegoor, A ^a   Visser, A ^a   Knol, D L ^a   Uitdehaag, B M J ^a   Barkhof, F ^a   Oudejans, C B M ^a   Polman, C H ^a   Killestein, J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; MYXOVIRUS RESISTANCE PROTEIN A; BETA INTERFERON; GUANINE NUCLEOTIDE BINDING PROTEIN; MYXOVIRUS RESISTANCE PROTEINS; NEUTRALIZING ANTIBODY;

ADULT; ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTRAST ENHANCEMENT; DISEASE ACTIVITY; DISEASE EXACERBATION; FEMALE; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RELAPSE; BLOOD; DISABILITY; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METHODOLOGY; MIDDLE AGED; PREDICTION AND FORECASTING; PROPORTIONAL HAZARDS MODEL; RECEIVER OPERATING CHARACTERISTIC; REGRESSION ANALYSIS;

ADULT; ANTIBODIES, NEUTRALIZING; COHORT STUDIES; DISABILITY EVALUATION; FEMALE; GENE EXPRESSION REGULATION; GTP-BINDING PROTEINS; HUMANS; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; REGRESSION ANALYSIS; RNA, MESSENGER; ROC CURVE; YOUNG ADULT;

EID: 77958185438     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181f6c556     Document Type: Article

References (25)

1. Lublin FD, Reingold SC, National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996;46:907-911.
2. Barkhof F, Filippi M, Miller DH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997;120:2059-2069.
3. Brex PA, Ciccarelli O, O'Riordan JI, Sailer M, Thompson AJ, Miller DH. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002;346:158-164.
4. Dalton CM, Brex PA, Miszkiel KA, et al. Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis. Ann Neurol 2002;52:47-53.
5. Miller D, Barkhof F, Montalban X, Thompson A, Filippi M. Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol 2005;4:281-288.
6. Malucchi S, Gilli F, Caldano M, et al. Predictive markers for response to interferon therapy in patients with multiple sclerosis. Neurology 2008;70:1119-1127.
7. van der Voort LF, Visser A, Knol DL, Oudejans CBM, Polman CH, Killestein J. Lack of Interferon-beta bioactiv-ity is associated with the occurrence of relapses in multiple sclerosis. Eur J Neurol 2009;16:1049-1052.
8. Bertolotto A, Gilli F, Sala A, et al. Evaluation of bioavailability of three types of IFN/3 in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification. J Immunol Methods 2001;256:141-152.
9. Ronni T, Melen K, Malygin A, Julkunen I. Control of IFN-inducible MxA gene expression in human cells. J Immunol 1993;150:1715-1726.
10. Lampe JB, Schneider-Schaulies S, AguzziA. Expression of the interferon-induced MxA protein in viral encephalitis. Neuropathol Appl Neurobiol 2003;29:273-279.
11. Lee PY, Kumagai Y, Li Y, et al. TLR7-dependent and FcyR-independent production of type I interferon in ex-perimental mouse lupus. J Exp Med 2008;205:2995-3006.
12. Wildenberg ME, van Helden-Meeuwsen CG, van de Merwe JP, Drexhage HA, Versnel MA. Systemic increase in type I interferon activity in Sjogren's syndrome: a putative role for plasmacytoid dendritic cells. Eur J Immunol 2008;38:2024-2033.
13. Al-Masri AN, Heidenreich F, Walter GF. Interferon-induced Mx proteins in brain tissue of multiple sclerosis patients. Eur J Neurol 2009;16:721-726.
14. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231.
15. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria." Ann Neurol 2005;58:840-846.
16. van der Voort LF, Kok A, Visser A, et al. Interferon-jS bioactivity measurement in multiple sclerosis: feasibility for routine clinical practice. Mult Scler 2009;15:212-218.
17. Rio J, Nos C, Tintore M, et al. Defining the response to interferon-/3 in relapsing-remitting multiple sclerosis patients. Ann Neurol 2006;59:344-352.
18. Feng X, Petraglia AL, Chen M, Byskosh PV, Boos MD, Reder AT. Low expression of interferon-stimulated genes in active multiple sclerosis is linked to subnormal phosphorylation of STAT1. J Neuroimmunol 2002;129:205-215.
19. Hesse D, Krakauer M, Lund H, et al. Spontaneous MxA mRNA expression is associated with low MRI disease activity in multiple sclerosis. Mult Scler 2007;13(2 suppl): S37-S38, P143.
20. Pachner AR, Warth JD, Pace A, et al. Effect of neutralizing antibodies on biomarker response to interferon beta: the INSIGHT Study. Neurology 2009;18:1493-1500.
21. Hesse D, Sellebjerg F, Sorensen PS. Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity. Neurology 2009;73:372-377.
22. van der Voort LF, Gilli F, Bertolotto A, et al. Multiple sclerosis: the clinical impact of neutralising antibodies to interferon-beta after cessation of therapy. Arch Neurol (in press 2010).
23. Sorensen PS, Hesse D, Krakauer M, Sondergaard HB, Sellebjerg F. Treatment-induced neutralising antibodies against recombinant interferon-/3 may block the bioactiv-ity of endogenous IFN-/3. Mult Scler 2009;15(3 suppl): S230, P763.
24. SominandaA, Menge T, Hemmer B, Hartung H-P, Kie-seier BC. Neutralising antibodies against interferon-beta neutralise natural interferon-beta. Mult Scler 2009;15(3 suppl):S134, P463.
25. Barkhof F. The clinico-radiological paradox in multiple sclerosis revisited. Curr Opin Neurol 2002;15:239-245.